fr   en
Clinical Studies
Phase :    
Announcement :   
Select a Pharma :
Select a product :
Select a disease :
Choose date:
[<<]      «      7   |   8   |   9   |   10   |   11   |   12   |   13   |   14   |   15   |   16   |   17      »      [57]
Date Phase Anouncement Biotech Pharma Product Disease Country Other
2009-11-23 I-IIa Launch Cytheris (France)   recombinant human interleukin-7 (CYT107) high risk pediatric solid tumors USA See details
2009-11-23 II Result Genfit (France)   GFT505 atherogenic dyslipidemia and abdominal obesity   See details
2009-11-19 IIb Result ImmuPharma (UK)   Lupuzor® The drug candidate corresponds to the sequence 131-151 of the 70k snRNP protein with a Serine phosphorylated in position 140. It modulates both the auto-reactive T and B cells involved in lupus in order to render the functioning of the immune system more appropriate while maintaining its overall efficacy. It was discovered by France's National Center for Scientific Research (Centre National de la Recherche Scientifique) and further developed by ImmuPharma and is now licensed to Cephalon (See BioPharmaceutiques issue 86 and systemic lupus erythematosus (SLE)   See details
2009-11-17 I Result TopoTarget (Denmark)   combination of belinostat and Velcade® (bortezomib) cancer USA See details
2009-11-17 II Launch Galapagos (Belgium)   Nanocort® ((prednisolone enclosed in liposomes) multiple sclerosis Belgium, Germany See details
2009-11-16 I Result ThromboGenics (Belgium) BioInvent (Sweden)   TB-403 (humanized monoclonal antibody targeting the angiogenic factor PlGF (placental growth factor) advanced solid tumours   See details
2009-11-16 IIb Result Addex Pharmaceuticals (Switzerland)   ADX10059 (metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator) gastroesophageal reflux disease (GERD)   See details
2009-11-16 I Result Xigen (Switzerland)   XG-102 (non-ATP competitive inhibitor of JNK (Jun-N terminal kinase) inflammation   See details
2009-11-13 I Result Nicox (France)   NCX 6560 (nitric oxide (NO)-donating HMG-CoA reductase inhibitor/NO-donating atorvastatin) cholesterol lowering   See details
2009-11-10 I-II Launch Mologen (Germany)   MGN1601 (cell-based gene therapy) advanced renal cancer Germany See details
2009-11-10 I Launch TRIN Pharma (Switzerland)   TRIN 2755 (novel triazene analog) solid tumors Germany See details
2009-11-10 IIa Result Cytos Biotechnology (Switzerland)   CYT006-AngQb (therapeutic vaccine) hypertension   See details
2009-11-09 IIb Launch 4SC (Germany)   4SC-101 (formerly SC12267) rheumatoid arthritis Poland, Romania, Bulgaria and the Czech Republic See details
2009-11-09 I-II Launch Morphosys (Germany)   MOR103 (fully human monoclonal antibody directed against Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) rheumatoid arthritis Germany and several European countries See details
2009-11-09 III Launch Genmab (Denmark)   Arzerra® (ofatumumab) relapsed or refractory diffuse large B-cell lymphoma   See details
[<<]      «      7   |   8   |   9   |   10   |   11   |   12   |   13   |   14   |   15   |   16   |   17      »      [57]